<DOC>
	<DOCNO>NCT01374438</DOCNO>
	<brief_summary>This study evaluate effect 150 mg MSDC-0160 take daily 90 day compare effect placebo change brain glucose utilization use FDG-PET cognition old person mild Alzheimer 's disease . Safety tolerability MSDC-0160 population also study . These result use design large study MSDC-0160 person mild Alzheimer 's disease .</brief_summary>
	<brief_title>3-month Study MSDC-0160 Effects Brain Glucose Utilization , Cognition &amp; Safety Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description>The specific objective examine feasibility conduct future large scale study efficacy MSDC-0160 person mild Alzheimer 's disease . Efficacy safety assess follow : 1 . Estimate effect size 150 mg daily MSDC-0160 versus placebo 3-month change brain glucose utilization use FDG-PET pre-specified region interest analysis . The priori region interest ( ROI ) include five bilateral region : posterior cingulate , parietal cortex ( angular gyrus ) , lateral temporal cortex , medial temporal cortex , anterior cingulate-medial frontal cortex . 2 . Estimate effect size MSDC-0160 versus placebo 3-month change brain glucose utilization , use FDG-PET voxel-based analysis . 3 . Estimate effect size MSDC-0160 treatment versus placebo 3-month change cognitive function determine global cognitive function neuropsychological battery 19 test . 4 . Estimate effect size MSDC-0160 versus placebo 3-month change cognitive function determine ADAS-Cog subscale . 5 . Estimate effect 3-months MSDC-0160 treatment versus placebo 9-item executive function scale . 6 . Explore whether baseline level peripheral inflammatory biomarkers ( HMW adiponectin , TNFα , IL-6 , hsCRP , FFA ) genotypes include , limited , apolipoprotein ε4 allele explain heterogeneity baseline level brain glucose utilization , MSDC-0160 user , 3-month brain glucose utilization . 7 . Explore whether change peripheral inflammatory biomarkers correlate change 3-month brain glucose utilization MSDC-0160 user . 8 . Investigate safety MSDC-0160 versus placebo use report early study termination adverse event .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Male female 5585 year age . 2 . Females either postmenopausal surgically sterilize . Males female partner childbearing potential must use contraception engage sexual intercourse . 3 . Diagnosis probable Alzheimer 's disease base NIAAA criterion MMSE score 20 great . 4 . Willing able take part six study visit 5month period , support caregiver need . 5 . Willing able sign inform consent document indicate understand purpose procedure require study willingness participate study , support caregiver need . 1 . Diagnosis diabetes , include use antidiabetic medication , fast plasma glucose &gt; 125 mg/dl Hemoglobin A1c &gt; 6.4 % . 2 . Unable participate FDGPET scanning , include : Inability cooperate/claustrophobia ( sedation offer protocol ) . Inability lie still scanner bed 40 minute . Total radiation dose exposure subject give year exceed limit annual total dose commitment 50 mSv ( 5 REMs ) . The two FDGPET scan result approximate exposure 10 mSv ( 1 REM ) . 3 . Diagnosis significant neurological/psychiatric disease AD , include , limited , follow : vascular dementia accord NINDSAIREN criterion , space occupy cerebral lesion , Huntington 's Disease , Parkinson 's Disease , normal pressure hydrocephalus , seizure . 4 . History heart failure ( include CHF ) . 5 . Previous cardiovascular event ( myocardial infarct , bypass surgery , PTCA ) within past 6 month prior screen . 6 . Inability undergo clinical ( 1.5T ) MRI brain without contrast lack usable ( less 12 month prior screen ) MRI record . Contraindications undergo MRI brain include , limited , pacemaker ; implantable cardioverter defibrillator ; cochlear implant ; cerebral aneurysm clip ; implant infusion pump ; implant nerve stimulators ; metallic splinter eye ; , magnetic , electronic mechanical implant clinical finding judgment investigator would pose potential hazard combination MRI . 7 . ALT and/or AST level twice upper limit normal ; bilirubin level exceed 2 mg/dL ; serum creatinine &gt; 1.5 mg/dL men &gt; 1.4 mg/dL woman . 8 . Current history severe unstable disorder ( medical psychiatric ) require treatment may make subject unlikely complete study . 9 . Malignancy ( nonmelanoma skin cancer ) within last 5 year . 10 . Known history HIV , hepatitis B , hepatitis C. 11 . Blood pressure great 160/100 mmHg . Subjects elevate BP allow discretion principal investigator . Individuals hypertension must stabilize current treatment regimen least 6 week prior screen need adjustment treatment regimen entire study period . 12 . Change medication treat Alzheimer 's disease within 3 month prior screen . Change medication treat condition within 6 week prior screen study period . 13 . Known suspected intolerance hypersensitivity study drug , closely related compound , state ingredient . 14 . History alcohol drug abuse within 6 month screen . 15 . Have participate investigational study receive investigational drug within 30 day 5 halflives ( whichever longer ) prior study drug administration . 16 . Single 12lead ECG demonstrate QTcB &gt; 450 msec clinically significant find screening . A single repeat ECG may do investigator 's discretion . 17 . Any surgical medical condition may significantly alter absorption drug substance include , limited , follow : history major gastrointestinal tract surgery , currently active inflammatory bowel syndrome . 18 . Evidence clinically relevant pathology investigator 's opinion could interfere study result put subject 's safety risk .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>cognitive function</keyword>
	<keyword>brain glucose utilization</keyword>
	<keyword>FDG-PET</keyword>
</DOC>